BOC Sciences Blog

delivery system

Advances in Non-Viral Vector Delivery Systems for Nucleic Acid Drugs

Nucleic acid drugs are mainly divided into two major categories: small nucleic acid drugs and mRNA. Small nucleic acid drugs, also known as oligonucleotide drugs, include antisense nucleotides (ASO), small […]

ADC payloads

History of ADC Payloads and Its Pharmacokinetic Profiles

Chemotherapy drugs are an important means of tumor treatment. At present, chemotherapy drugs based on different mechanisms have been developed, which can act on the initial raw materials such as […]

ADC toxicity

Effects of ADC Toxicity and Optimization Strategies

So far, the FDA and EMA have approved six ADC drugs for patients with solid tumors. Fig. 1 depicts the composition of each ADC (targeting antigen, mAb type, payload, and linker), […]

inhibitors

Peptide Covalent Inhibitors Targeting Protein-Protein Interactions

Covalent drugs refer to those drug molecules that form strong bonds with receptors through the formation of covalent bonds. It all began with aspirin in 1899, gained prominence with ibrutinib in […]

ligands in PROTACs

Thalidomide Analogs and Other CRBN Ligands in PROTACs

History of Thalidomide During the 1950s-1960s, thalidomide was widely used as an antiemetic for pregnant women, leading to a tragic outcome with thousands of cases of malformed babies. However, in 1965, […]

Trastuzumab ADC

Review of Structure-Activity Relationship Based on Trastuzumab ADC

Many approaches have been developed to improve the physical/chemical properties, potency and selectivity of antibody-drug conjugates (ADCs). Trastuzumab (Tz), a monoclonal antibody targeting HER2, was approved by the FDA in […]

deuterated drugs

Deuterated Drugs Research Progress

What are Deuterated Drugs? Deuterated drugs are medications obtained by substituting hydrogen atoms at specific positions on drug molecules with deuterium atoms. The most widely used application involves replacing carbon-hydrogen (C-H) bonds with […]

Cyclic Peptide Inhibitors of KRAS

Challenges and Advantages in the Development of Cyclic Peptide Inhibitors of KRAS

Over the past several decades, direct inhibition of the RAS family of oncogenic proteins has been a significant challenge in the field of drug development. Despite accounting for approximately 30% […]

Glycoconjugate Vaccine

Composition and Immune Mechanism of Glycoconjugate Vaccine

A conjugate vaccine is a type of vaccine that combines a weak or non-toxic part of a disease-causing microorganism (such as a bacteria or virus) with a carrier protein. The […]

RNA Synthesis

Circular RNA Synthesis

The Background of Circular RNA Synthesis In recent years, nucleic acid therapy involving various types of ribonucleic acids (RNAs), including messenger RNA (mRNA), small interfering RNA (siRNA), and microRNA (miRNA), […]